Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Ductal Adenocarcinoma (PDAC): early-phase trial registry
16 of 17 indexed Pancreatic Ductal Adenocarcinoma (PDAC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 16 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Pancreatic Ductal Adenocarcinoma (PDAC): 17 US clinical trials tracked, 16 recruiting.
Pancreatic Ductal Adenocarcinoma (PDAC) is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Revolution Medicines, running 3 of these trials.
Enrollment posture brief
Registry condition pancreatic-ductal-adenocarcinoma-pdac
OPEN 16 | RECR 94% | LATE 1 | EARLY 15 | RANK #1004 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Substance Use Disorder (SUD) (94% recruiting · 16 trials)
Pancreatic Ductal Adenocarcinoma (PDAC) lists 16 open slots (94% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Ductal Adenocarcinoma (PDAC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Ductal Adenocarcinoma (PDAC) is recruiting above its size-band peers.
16 of 17 indexed trials (94.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pancreatic Ductal Adenocarcinoma (PDAC) research.
Revolution Medicines accounts for 3 of 17 trials (17.6%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Pancreatic Ductal Adenocarcinoma (PDAC) enrolment sits around 200 participants.
Median target enrolment is 200 among the 17 trials that report a genuine target (sentinel values excluded). 7 of those (41.2%) plan for fewer than 100 participants.
-
Pancreatic Ductal Adenocarcinoma (PDAC) research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
City of Hope Medical Center
NCT07224750
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines
NCT05379985
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines
NCT06040541
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Kura Oncology
NCT06026410
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
NCT07223047
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
EMD Serono Research & Development Institute
NCT06710132
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE
NCT07217717
EUS-RFA PANCARDINAL-1 Trial
The University of Texas Health Science Center, Houston
NCT04990609
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
ProDa BioTech
NCT06182072
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03977233
A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited
NCT07450859
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
University of California, San Diego
NCT06639724
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
University of Colorado, Denver
NCT07030283
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT04083599
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Ductal Adenocarcinoma (PDAC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Ductal Adenocarcinoma (PDAC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Ductal Adenocarcinoma (PDAC) page
17 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Pancreatic Ductal Adenocarcinoma (PDAC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Revolution Medicines sponsors the most Pancreatic Ductal Adenocarcinoma (PDAC) trials on record, review their full trial history before evaluating a specific study. See Revolution Medicines's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Ductal Adenocarcinoma (PDAC) condition card totals 17 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.